TG Therapeutics reports Q4 results

by
Contributor since / Followers

10 months ago

TG Therapeutics press release (NASDAQ:TGTX): Q4 GAAP EPS of -$0.09 beats by $0.02.
Revenue of $43.97M
Cash Position and Financial Guidance: Cash, cash equivalents and investment securities were $217.5 million as of December 31, 2023.
2024 Target BRIUMVI Guidance
- BRIUMVI U.S. net

Tags: TGTX